Labopharm Once-Daily Tramadol NDA Planned For Second Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will conduct an additional pivotal trial in support of moderate to moderately-severe pain indication following discussions with FDA. Biovail’s once-daily tramadol Ralivia ER is pending at FDA with a PDUFA date of Oct. 31.